16 February 2026
16 February 2026
The Stealth AXiS system architecture allows support for a variety of surgeon preferences and clinical complexities.
Immunic will issue 229.1 million pre-funded warrants at $0.873 each to select investors, raising upfront proceeds of $200m.
The decision by the EC was supported by data from the Myasthenia Gravis Inebilizumab Trial.
The device recently received clearance from the FDA under the 510(k) process.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
